Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Read more about Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. Read more about Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
Targeting activated KIT signaling for melanoma therapy. Read more about Targeting activated KIT signaling for melanoma therapy.
Re-examining racial disparities in prostate cancer outcomes. Read more about Re-examining racial disparities in prostate cancer outcomes.
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. Read more about Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Reply to M.-E. Percival et al and L.B. Saltz. Read more about Reply to M.-E. Percival et al and L.B. Saltz.
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. Read more about Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. Read more about Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.
